SAN DIEGO--(BUSINESS WIRE)--Polynoma LLC, a U.S. oncology-focused biopharmaceutical company within Hong Kong-based CK Life Sciences Int’l., (Holdings) Inc., today announced the start of a Phase III clinical trial program for POL 103A, the Company’s novel melanoma vaccine. Polynoma’s global, multi-center, double-blind, placebo-controlled Melanoma Antigen Vaccine Immunotherapy Study (MAVIS) is designed to enroll a total of 1059 patients with resected Stage IIb, IIc or III melanoma. The trial is being conducted under a Special Protocol Assessment (SPA) agreed upon with the U.S. Food and Drug Administration (FDA).
